
News|Articles|June 30, 2026
5 FDA Decisions for Primary Care to Know from June 2026
Author(s)Sydney Jennings
Fact checked by: Abigail Brooks, MA
Recent FDA actions include updates on COVID-19 prophylaxis, ADHD, PTSD neuromodulation, and pediatric psoriasis and psoriatic arthritis care.
Advertisement
Advertisement
In June, the
Related to this article

The FDA approved at-home dexmedetomidine film for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.

Ascletis submits an FDA IND for ASC30_39, an oral GLP-1–amylin obesity combination supported by preclinical data.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.

Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.

FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.

FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Advertisement
Advertisement

